Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
33
BCLI Quote, Financials, Valuation and Earnings
Last price:
$1.18
Seasonality move
:
53.36%
Day range:
$1.18 - $1.23
52-week range:
$0.72 - $6.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
219.5K
Avg. volume:
433.2K
1-year change:
-80.2%
Market cap:
$9.5M
Revenue:
--
EPS (TTM):
-$2.07
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Brainstorm Cell Therapeutics has 1215.28% upside to fair value with a price target of $15.78 per share.
BCLI vs. S&P 500
-
Over the past 5 trading days, Brainstorm Cell Therapeutics has underperformed the S&P 500 by -3.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Brainstorm Cell Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Brainstorm Cell Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Brainstorm Cell Therapeutics reported revenues of --.
Earnings Growth
-
Brainstorm Cell Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Brainstorm Cell Therapeutics reported earnings per share of -$0.45.
Enterprise value:
9.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$24.5M | -$18.8M | -$12.3M | -$2.5M | -$3.1M | |
| EBITDA | -$24.2M | -$18.5M | -$12.1M | -$2.4M | -$3M | |
| Diluted EPS | -$9.75 | -$4.80 | -$2.07 | -$0.75 | -$0.45 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $41M | $19.3M | $2.9M | $1.3M | $2.3M | |
| Total Assets | $48.6M | $25.8M | $7.9M | $3.3M | $3.6M | |
| Current Liabilities | $8.2M | $7.4M | $10.4M | $6.8M | $10.9M | |
| Total Liabilities | $12.4M | $11.3M | $12.7M | $8.9M | $11M | |
| Total Equity | $36.2M | $14.5M | -$4.8M | -$5.6M | -$7.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.6M | -$19.5M | -$7.7M | -$3.1M | -$1.6M | |
| Cash From Investing | $3M | $188K | -- | -- | -- | |
| Cash From Financing | $3.5M | $18.3M | $8.5M | $2.5M | $3.1M | |
| Free Cash Flow | -$19.6M | -$19.5M | -$7.7M | -$3.1M | -$1.6M | |
BCLI
Sector
Market Cap
$9.5M
$34.4M
Price % of 52-Week High
19.05%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-80.2%
-37.36%
Beta (5-Year)
0.223
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.21
200-day SMA
Sell
Level
$1.59
Bollinger Bands (100)
Sell
Level
1.02 - 1.46
Chaikin Money Flow
Sell
Level
-86.9M
20-day SMA
Buy
Level
$1.18
Relative Strength Index (RSI14)
Buy
Level
51.66
ADX Line
Buy
Level
24.75
Williams %R
Neutral
Level
-40
50-day SMA
Buy
Level
$1.18
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
208.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Stock Forecast FAQ
In the current month, BCLI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BCLI average analyst price target in the past 3 months is $15.78.
-
Where Will Brainstorm Cell Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Brainstorm Cell Therapeutics share price will rise to $15.78 per share over the next 12 months.
-
What Do Analysts Say About Brainstorm Cell Therapeutics?
Analysts are divided on their view about Brainstorm Cell Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Brainstorm Cell Therapeutics is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Brainstorm Cell Therapeutics's Price Target?
The price target for Brainstorm Cell Therapeutics over the next 1-year time period is forecast to be $15.78 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BCLI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Brainstorm Cell Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BCLI?
You can purchase shares of Brainstorm Cell Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Brainstorm Cell Therapeutics shares.
-
What Is The Brainstorm Cell Therapeutics Share Price Today?
Brainstorm Cell Therapeutics was last trading at $1.18 per share. This represents the most recent stock quote for Brainstorm Cell Therapeutics. Yesterday, Brainstorm Cell Therapeutics closed at $1.20 per share.
-
How To Buy Brainstorm Cell Therapeutics Stock Online?
In order to purchase Brainstorm Cell Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
